PubMed COVID-19 Clinical Care

CONCLUSIONS: Telepharmacy represents a reliable and time-efficient alternative to in-person BPMHs.

The COVID-19 pandemic heralded unprecedented resource mobilisation and global scientific collaboration to rapidly develop effective vaccines. Regrettably, vaccine distribution has been inequitable, particularly in Africa where manufacturing capacity

CONCLUSIONS: Managing adherence to public health measures is critical when it comes to highly infectious diseases. Our findings suggest that efficient information campaigns to increase adherence to public health measures should focus on calibrating

Recent technological advances and substantial cost reductions have made the genomic surveillance of pathogens during pandemics feasible. Our paper focuses on full genome sequencing as a tool that can serve two goals: the estimation of variant

CONCLUSIONS: Reopening access to family members during the Covid-19 period is possible, sustainable and beneficial. The use of flexible and motivational management principles by the coordinator were crucial in ensuring a family-centred approach

CONCLUSION: Nearly half of the patients declined for ECMO consideration were alive on day 7. More information on patient trajectory and long-term outcomes in declined referrals is needed to refine selection criteria.

Curiosity appears to be the driving force for humans to find new information, but despite its general relevance, only a few studies investigated the underlying mechanisms of curiosity. Kang et al. (Psychol Sci 20(8):963-973, 2009) and Dubey and

The COVID-19 pandemic demonstrates the great importance of risk and crisis communication. In a dynamic situation, authorities and policymakers face the challenge of dealing with a large amount of data, reviewing it and communicating it in a way that

ConspectusNative mass spectrometry is nowadays widely used for determining the mass of intact proteins and their noncovalent biomolecular assemblies. While this technology performs well in the mass determination of monodisperse protein assemblies

CONCLUSIONS: In a phase 2 study of non-hospitalized adults with mild-to-moderate COVID-19, oral camostat did not accelerate viral clearance nor time to symptom improvement, nor reduce hospitalizations or deaths. (Funded by the National Institutes of